Reunion Neuroscience Inc. Announces FDA Clearance of IND Application to Initiate a Phase 2 Study of RE104 for the Treatment of Postpartum Depression – Psychedelic Alpha
WILMINGTON, Del., Sept. 18, 2023 (GLOBE NEWSWIRE) — Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved